Atropos Health vs OpenEvidence (2026)
These two look like competitors and are actually sequential, which is the most useful thing a buyer can know about them. OpenEvidence searches what has been published and returns a cited answer in seconds. Atropos, spun out of Stanford's Green Button project, generates evidence that does not exist yet, running a publication grade observational study across a federated network of more than 300 million de identified records to answer the question no trial covers. So the honest framing is that you reach for OpenEvidence when the literature has probably answered this, and for Atropos when you already know it has not. Atropos also holds the better privacy architecture, linking records only at query time rather than pooling them. It publishes no price, no attestation and no trust centre, so the diligence burden sits entirely with the buyer.
- It answers the question the literature cannot: what happened to patients like this one, generated on demand from a federated network the company describes as exceeding 300 million anonymised records rather than retrieved from a paper someone already wrote.
- The privacy architecture is the disclosure. A federated network with nodal de identification links records only at query time rather than assembling a central warehouse, which removes the aggregation risk instead of governing it.
- Output is a publication grade observational study rather than a summary, which means the method is inspectable and the result can be argued with, defended in a committee or submitted.
- Eleven independent studies evaluating this product between 2024 and 2026, identified through a systematic review, against a vendor with no located third party attestation or trust centre at all.
- It is free to verified United States clinicians and takes seconds, where the alternative publishes no price of any kind, no unit and no indication of whether it is sold per query, per seat or per data source.
- Named partnerships with the New England Journal of Medicine, JAMA and Cochrane, plus web, mobile and Epic embedded delivery, which is the practical answer at the point of care rather than in a research meeting.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Atropos Health and OpenEvidence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Atropos Health | OpenEvidence |
|---|---|---|
| Primary category | Clinical Reference & Evidence | Clinical Reference & Evidence |
| Founded | 2020 | 2021 |
| Headquarters | Palo Alto, California | Miami, Florida |
| Website | atroposhealth.com | openevidence.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Atropos Health its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against OpenEvidence, Atropos Health grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards OpenEvidence its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against Atropos Health, OpenEvidence grades higher on HIPAA and BAA Posture, Security Certifications and Trust Center and Commercial Transparency. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Atropos Health or OpenEvidence?
On the axes where the AI Health Index separates them, Atropos Health grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure, and OpenEvidence grades higher on HIPAA and BAA Posture, Security Certifications and Trust Center and Commercial Transparency. Atropos Health leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Atropos Health and OpenEvidence differ most?
The widest separation the AI Health Index records between Atropos Health and OpenEvidence is on Model and Technology Transparency, where Atropos Health grades A and OpenEvidence grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Atropos Health and OpenEvidence grade the same?
The AI Health Index grades Atropos Health and OpenEvidence the same on several axes, including AI Centrality, FDA and Regulatory Status and EHR and Interoperability Depth. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Atropos Health and OpenEvidence not disclosed?
At the last review, at least one of Atropos Health and OpenEvidence published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These products answer different questions and should not be treated as substitutes: one retrieves and synthesises published evidence, the other generates new observational evidence from real world data. Atropos publishes no pricing of any kind, no security attestation, trust centre or third party certification, and its security language is atmospheric rather than specific.
Observational evidence generated on demand carries confounding and selection risks that a rapid workflow does not remove, so the methodology of each generated study is the thing to review rather than the speed of it. OpenEvidence is funded by pharmaceutical and device advertising alongside its answers, governed by a published policy.